Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cortecs buys cancer antigen:

This article was originally published in Clinica

Executive Summary

Cortecs International has bought the exclusive rights to develop a test for nasopharyngeal cancer from CRCT, the technology transfer arm of the UK Cancer Research Campaign. The technology is based on abnormal response to Epstein-Barr virus infection in people with nasopharyngeal cancer, which is the most common cancer in Chinese men and number two in Chinese women. Cortecs has also acquired an antigen for early detection of TB.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT089786

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel